"Farmasintez" realizes the Skolkovo project
"Farmasintez" and the resident of a cluster of biomedical technologies Fund "Skolkovo" "the Farm Fusion" signed the license agreement on commercialization of an innovative preparation from PF-114 leukosis. The medicinal candidate of PF-114 – the targetny preparation of the 3rd generation developed by the Russian company "Farm Fusion", is intended for treatment chronic miyeloleykoza (HML) which is not giving in to therapy by preparations of the 1st and 2nd generations. By results of multicenter clinical trial of the 1st phase in the target...